Lupus Myocarditis: Initial Presentation and Longterm Outcomes in a Multicentric Series of 29 Patients

29 patients with definite systemic lupus erythematosus (SLE) and lupus myocarditis (median age 30 years, 1/8.6 M/F ratio) from 3 French university hospitals. Key inclusion: definite SLE (≥4 ACR criteria) and myocarditis defined by ≥2 of: high serum troponin, new/worsening echocardiography changes (impaired LVEF), or delayed gadolinium enhancement on cMRI.

Immunosuppressive therapy according to clinical physician's habits, including corticosteroids (n=28), cyclophosphamide (n=16), intravenous immunoglobulins (n=8), and/or mycophenolate mofetil (n=2).

LVEF recovery 1 month after baseline (LVEF > 55% evaluated using echocardiography)surrogate